Utah Medical ProductsUTMD
UTMD
About: Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Employees: 167
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 108 [Q1] → 108 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2% less capital invested
Capital invested by funds: $125M [Q1] → $122M (-$2.71M) [Q2]
1.87% less ownership
Funds ownership: 68.06% [Q1] → 66.19% (-1.87%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for UTMD.
Financial journalist opinion
Negative
Zacks Investment Research
3 weeks ago
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
Neutral
Accesswire
4 weeks ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / July 29, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on October 2, 2025 to stockholders of record at the close of business on September 17, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Negative
The Motley Fool
1 month ago
Utah Medical Products Reports Q2 Decline
Utah Medical Products Reports Q2 Decline
Neutral
Accesswire
1 month ago
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025
SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent with overall beginning-of-year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Positive
Seeking Alpha
1 month ago
Utah Medical Products: Deep Discount Is Drawing One Legendary Investor's Interest
I reiterate my strong buy on UTMD, citing its robust balance sheet, disciplined capital allocation, and 43% upside to my $82.22 price target. Revenue headwinds appear to be stabilizing, with legendary value investor Charles Brandes taking a 7.4% stake, signaling renewed institutional interest. Key risks include Filshie Clip litigation, declining China sales, and succession planning, but UTMD's undervaluation and cash reserves limit downside.
Neutral
Accesswire
3 months ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Positive
Seeking Alpha
3 months ago
Stock Picks From Seeking Alpha's April 2025 New Analysts
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.
Negative
Zacks Investment Research
3 months ago
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1%
UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
Neutral
Accesswire
3 months ago
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025
SALT LAKE CITY, UT / ACCESS Newswire / April 29, 2025 / In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. Summary of results.
Positive
Seeking Alpha
4 months ago
Utah Medical Products: Quietly Profitable--A Deep Value Gem Hiding In The Open
Utah Medical Products develops and manufactures medical devices focused on women's health, obstetrics, gynecology, and blood pressure monitoring. The company's stock price has declined due to a drop in sales from a key U.S. customer, weaker performance in international markets, and ongoing litigation. Despite recent challenges, the company has a consistent track record of profitability, a fortress balance sheet, and a disciplined capital allocator in the CEO.
Charts implemented using Lightweight Charts™